House dust differences between Amish and Hutterite communities affect immune development and asthma risk, according to a study co-authored by University of Arizona Health Sciences researcher Dr. Donata Vercelli published Aug. 4 in the New England Journal of Medicine.Continue reading
Category Archives: AZBio News
$400,000 grant from the National Institute of Health (NIH) to test and refine a new antibacterial material,
Molded in clay: new antibacterials to kill germs
Calimmune CEO Louis Breton Named to PharmaVOICE 100 for 2016
Calimmune, Inc., a clinical-stage gene therapy company, is pleased to announce that its Chief Executive Officer, Louis Breton, has been selected by PharmaVOICE magazine as one of the top 100 most inspirational and extraordinary leaders in the life sciences industry for 2016.
Castle Biosciences Announces Clinical Results of Melanoma Gene Expression Test in Stage I and II Cohort Study at 2016 AAD Summer Meeting
Study confirms DecisionDx-Melanoma accurately predicts metastatic risk in Stage I or Stage II patients who have no sign of disease beyond original tumorContinue reading
HTG Molecular Diagnostics Obtains CE IVD Mark for Its HTG EdgeSeq DLBCL Cell of Origin Assay and HTG EdgeSeq System
HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications, today announced that it has obtained CE-IVD marking for its HTG EdgeSeq DLBCL Cell of Origin Assay and next-generation sequencing (NGS) based HTG EdgeSeq system.Continue reading
UA Study of Lung Disorders Gets $11.4M Boost
The National Heart, Lung and Blood Institute program has granted $11.4 million to a project led by Dr. Joe G.N. “Skip” Garcia, the UA’s vice president for health sciences.Continue reading
HTG Molecular Diagnostics and Firalis Announce Agreement to Develop a Theranostic Tool to Predict Response to Anti-TNF-alpha Therapies for Rheumatoid Arthritis
HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM) (“HTG”), a provider of instruments and reagents for molecular profiling applications, and Firalis S.A. (“Firalis”), a provider of bioanalytical services and biomarker-based products to biopharma, to biotechnology companies, and to academia, announced an agreement to develop a next‑generation sequencing (NGS)-based theranostic tool to identify likely non-responders from responders to anti‑TNFα therapy for rheumatoid arthritis (RA).Continue reading
Iron Horse Diagnostics, Inc. Announces License Agreement With Global IVD Powerhouse for First-to-Market ALS Diagnostic Test
Euroimmun granted license to launch first ALS biologic diagnostic test in Europe
Continue reading
Dr Josh LaBaer advances disease research, claims important award
Josh LaBaer, M.D., PhD., a leading researcher in the rapidly expanding field of proteomics, has just been awarded the 2016 Translational Proteomics Award from the Human Proteome Organization (or HUPO). The prestigious award recognizes professor LaBaer’s distinguished scientific achievements in the field of translational proteomics science.Continue reading
Beacon Biomedical Inc. Opens R&D and CLIA Laboratory To Advance Early Cancer Detection Research
Beacon Biomedical, Inc., a privately held company focused on developing highly accurate laboratory and point-of-care blood tests for colorectal cancer screening and its early detection, has opened new Corporate Offices and their R&D-CLIA laboratory at the Center for Entrepreneurial Innovation (CEI) in Phoenix.Continue reading